|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4-5
|
|
pubmed:dateCreated |
2000-3-21
|
|
pubmed:abstractText |
This study was designed to examine the influence of a macrolide antibiotic, roxithromycin (RXM), on the production of pro-inflammatory cytokines, interleukin (IL)-1beta and tumor necrosis factor (TNF)-alpha. In the first experiments, we examined the effect of RXM on in vitro cytokine production from lipopolysaccharide (LPS)-stimulated human peripheral blood monocytes. The monocytes were cultured in the presence of various doses of the agent. After 24 h, the culture supernatants were obtained and assayed for IL-1beta and TNF-alpha contents by enzyme-linked immunosorbent assay. RXM suppressed the in vitro production of IL-1beta and TNF-alpha in response to LPS stimulation. This was dose dependent and first noted at a concentration of as little as 0.05 microg/ml, which is much lower than therapeutic blood levels. In the second part of the experiments, we examined the influence of RXM on the appearance of IL-1beta and TNF-alpha in mouse lung extract induced by LPS inhalation. RXM was administered orally into BALB/c mice at a single dose of 2.5 mg/kg once a day for 5-12 weeks. These mice were then instilled with LPS into the trachea and examined for the presence of cytokines in aqueous lung extracts. Pretreatment of mice with RXM for 5 weeks did not influence of the appearance of both IL-1beta and TNF-alpha in aqueous lung extracts. However, pretreatment for more than 7 weeks dramatically suppressed the cytokine appearance in the extracts.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/10704073-1374612,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10704073-1416647,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10704073-1654910,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10704073-1688572,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10704073-1736737,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10704073-1995224,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10704073-2310089,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10704073-3395477,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10704073-3731922,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10704073-7920033,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10704073-8421430,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10704073-856009
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0962-9351
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
199-204
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:10704073-Administration, Inhalation,
pubmed-meshheading:10704073-Administration, Oral,
pubmed-meshheading:10704073-Animals,
pubmed-meshheading:10704073-Anti-Bacterial Agents,
pubmed-meshheading:10704073-Cells, Cultured,
pubmed-meshheading:10704073-Cytokines,
pubmed-meshheading:10704073-Humans,
pubmed-meshheading:10704073-Instillation, Drug,
pubmed-meshheading:10704073-Interleukins,
pubmed-meshheading:10704073-Lipopolysaccharides,
pubmed-meshheading:10704073-Lung,
pubmed-meshheading:10704073-Lymphocytes,
pubmed-meshheading:10704073-Male,
pubmed-meshheading:10704073-Mice,
pubmed-meshheading:10704073-Mice, Inbred BALB C,
pubmed-meshheading:10704073-Roxithromycin,
pubmed-meshheading:10704073-Trachea,
pubmed-meshheading:10704073-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Suppressive activity of a macrolide antibiotic, roxithromycin, on pro-inflammatory cytokine production in vitro and in vivo.
|
|
pubmed:affiliation |
Department of Otolaryngology, School of Medicine, Showa University, Tokyo, Japan.
|
|
pubmed:publicationType |
Journal Article
|
